Recent VRPX News
- Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™ • Business Wire • 04/30/2024 11:30:00 AM
- Virpax Pharmaceuticals Reports 2023 Year-End Results • Business Wire • 03/26/2024 11:30:00 AM
- Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price • Business Wire • 02/27/2024 12:31:00 PM
- Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. • Business Wire • 02/27/2024 12:30:00 PM
- Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research • Business Wire • 02/07/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:26:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:25:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:25:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:24:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:23:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:23:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:22:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:21:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 12:30:32 PM
- Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting • Business Wire • 12/29/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 01:30:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/07/2023 02:08:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 01:58:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/07/2023 01:50:05 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/21/2023 09:57:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 12:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 12:15:12 PM
- Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing • Business Wire • 11/17/2023 12:10:00 PM
- Virpax Pharmaceuticals Announces Leadership Transition • Business Wire • 11/17/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:51:23 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM